OncoCyte Corporation (OCX)

Market Cap	81.22M
Revenue (ttm)	1.88M
Net Income (ttm)	-60.93M
Shares Out	28.60M
EPS (ttm)	-4.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,001
Open	2.790
Previous Close	2.830
Day's Range	2.790 - 2.840
52-Week Range	1.922 - 4.750
Beta	0.98
Analysts	Strong Buy
Price Target	4.56 (+60.56%)
Earnings Date	May 14, 2025

About OCX

OncoCyte Corporation, a precision diagnostics company in the United States and internationally. It develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. The company is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. It also offers VitaGraft Kidney, a blood-based transplant monitoring test that quant...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2009
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: OCX
• Website: https://www.oncocyte.com

Financial Performance

In 2024, OncoCyte's revenue was $1.88 million, an increase of 25.15% compared to the previous year's $1.50 million. Losses were -$60.93 million, 112.1% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for OCX stock is "Strong Buy." The 12-month stock price forecast is $4.56, which is an increase of 60.56% from the latest price.

Price Target

$4.56

(60.56% upside)

Analyst Consensus: Strong Buy